User menu

Localisation and mechanism of renal retention of radiolabelled somatostatin analogues

Bibliographic reference Melis, M ; Krenning, EP ; Bernard, BG ; Barone, Raffaella ; Visser, TJ ; et. al. Localisation and mechanism of renal retention of radiolabelled somatostatin analogues. In: European Journal of Nuclear Medicine and Molecular Imaging, Vol. 32, no. 10, p. 1136-43 (2005)
Permanent URL
  1. Krenning EP, Kwekkeboom DJ, Bakker WH, Breeman WA, Kooij PP, Oei HY, et al. Somatostatin receptor scintigraphy with [111In-DTPA-d-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1,000 patients. Eur J Nucl Med 1993;20:716–31
  2. Kwekkeboom DJ, Krenning EP. Somatostatin receptor imaging. Semin Nucl Med 2002;32:84–91
  3. de Jong M, Kwekkeboom D, Valkema R, Krenning EP. Radiolabelled peptides for tumour therapy: current status and future directions. Plenary lecture at the EANM 2002. Eur J Nucl Med Mol Imaging 2003;30:463–9
  4. Krenning EP, Kwekkeboom DJ, Valkema R, Pauwels S, Kvols LK, De Jong M. Peptide receptor radionuclide therapy. Ann N Y Acad Sci 2004;1014:234–45
  5. Otte A, Herrmann R, Heppeler A, Behe M, Jermann E, Powell P, et al. Yttrium-90 DOTATOC: first clinical results. Eur J Nucl Med 1999;26:1439–47
  6. Paganelli G, Zoboli S, Cremonesi M, Bodei L, Ferrari M, Grana C, et al. Receptor-mediated radiotherapy with 90Y-DOTA-d-Phe1-Tyr3-octreotide. Eur J Nucl Med 2001;28:426–34
  7. Emami B., Lyman J., Brown A., Cola L., Goitein M., Munzenrider J.E., Shank B., Solin L.J., Wesson M., Tolerance of normal tissue to therapeutic irradiation, 10.1016/0360-3016(91)90171-y
  8. De Jong M, Valkema R, Van Gameren A, Van Boven H, Bex A, Van De Weyer EP, et al. Inhomogeneous localization of radioactivity in the human kidney after injection of [111In-DTPA]octreotide. J Nucl Med 2004;45:1168–71
  9. Nagai J, Takano M. Molecular aspects of renal handling of aminoglycosides and strategies for preventing the nephrotoxicity. Drug Metab Pharmacokinet 2004;19:159–70
  10. Christensen EI, Birn H. Megalin and cubilin: synergistic endocytic receptors in renal proximal tubule. Am J Physiol Renal Physiol 2001;280:F562–73
  11. Verroust PJ, Christensen EI. Megalin and cubilin—the story of two multipurpose receptors unfolds. Nephrol Dial Transplant 2002;17:1867–71
  12. Christensen EI, Nielsen S, Moestrup SK, Borre C, Maunsbach AB, de Heer E, et al. Segmental distribution of the endocytosis receptor gp330 in renal proximal tubules. Eur J Cell Biol 1995;66:349–64
  13. Bakker WH, Krenning EP, Reubi JC, Breeman WA, Setyono-Han B, de Jong M, et al. In vivo application of [111In-DTPA-d-Phe1]-octreotide for detection of somatostatin receptor-positive tumors in rats. Life Sci 1991;49:1593–601
  14. de Jong M, Breeman WA, Bernard BF, Bakker WH, Schaar M, van Gameren A, et al. [177Lu-DOTA(0),Tyr3] octreotate for somatostatin receptor-targeted radionuclide therapy. Int J Cancer 2001;92:628–33
  15. Breeman WA, De Jong M, Visser TJ, Erion JL, Krenning EP. Optimising conditions for radiolabelling of DOTA-peptides with 90Y, 111In and 177Lu at high specific activities. Eur J Nucl Med Mol Imaging 2003;30:917–20
  16. de Jong M, Breeman WA, Bakker WH, Kooij PP, Bernard BF, Hofland LJ, et al. Comparison of 111In-labeled somatostatin analogues for tumor scintigraphy and radionuclide therapy. Cancer Res 1998;58:437–41
  17. Akizawa H, Arano Y, Mifune M, Iwado A, Saito Y, Uehara T, et al. Significance of 111In-DTPA chelate in renal radioactivity levels of 111In-DTPA-conjugated peptides. Nucl Med Biol 2001;28:459–68
  18. Ten Bokum AM, Rosmalen JG, Hofland LJ, Krenning EP, Van Hagen PM, Breeman WA. Tissue distribution of octreotide binding receptors in normal mice and strains prone to autoimmunity. Nucl Med Commun 2002;23:1009–17
  19. Mogensen CE, Solling. Studies on renal tubular protein reabsorption: partial and near complete inhibition by certain amino acids. Scand J Clin Lab Invest 1977;37:477–86
  20. Behr TM, Goldenberg DM, Becker W. Reducing the renal uptake of radiolabeled antibody fragments and peptides for diagnosis and therapy: present status, future prospects and limitations. Eur J Nucl Med 1998;25:201–12
  21. Hofland LJ, Lamberts SW, van Hagen PM, Reubi JC, Schaeffer J, Waaijers M, et al. Crucial role for somatostatin receptor subtype 2 in determining the uptake of [111In-DTPA-d-Phe1]octreotide in somatostatin receptor-positive organs. J Nucl Med 2003;44:1315–21
  22. Christensen EI, Rennke HG, Carone FA. Renal tubular uptake of protein: effect of molecular charge. Am J Physiol 1983;244:F436–41
  23. Akizawa H, Arano Y, Mifune M, Iwado A, Saito Y, Mukai T, et al. Effect of molecular charges on renal uptake of 111In-DTPA-conjugated peptides. Nucl Med Biol 2001;28:761–8
  24. Bernard BF, Krenning EP, Breeman WA, Rolleman EJ, Bakker WH, Visser TJ, et al. d-Lysine reduction of indium-111 octreotide and yttrium-90 octreotide renal uptake. J Nucl Med 1997;38:1929–33
  25. Behr TM, Sharkey RM, Juweid ME, Blumenthal RD, Dunn RM, Griffiths GL, et al. Reduction of the renal uptake of radiolabeled monoclonal antibody fragments by cationic amino acids and their derivatives. Cancer Res 1995;55:3825–34
  26. Kramer JH, Gonick HC. Experimental Fanconi syndrome: I. Effect of maleic acid on renal cortical Na–K-ATPase activity and ATP levels. J Lab Clin Med 1970;76:799–808
  27. Nagai J, Tanaka H Nakanishi N, Murakami T, Takano M. Role of megalin in renal handling of aminoglycosides. Am J Physiol Renal Physiol 2001;281:F337–44
  28. de Jong M, Rolleman EJ, Bernard BF, Visser TJ, Bakker WH, Breeman WA, et al. Inhibition of renal uptake of indium-111-DTPA-octreotide in vivo. J Nucl Med 1996;37:1388–92
  29. Rolleman EJ, Krenning EP, Van Gameren A, Bernard BF, De Jong M. Uptake of [111In-DTPA0]octreotide in the rat kidney is inhibited by colchicine and not by fructose. J Nucl Med 2004;45:709–13
  30. Gutmann EJ, Niles JL, McCluskey RT, Brown D. Colchicine-induced redistribution of an apical membrane glycoprotein (gp330) in proximal tubules. Am J Physiol 1989;257:C397–407
  31. Safirstein Robert, Winston Jonathan, Goldstein Marvin, Moel Donald, Dikman Steven, Guttenplan Joseph, Cisplatin Nephrotoxicity, 10.1016/s0272-6386(86)80111-1
  32. Takano M, Nakanishi N, Kitahara Y, Sasaki Y, Murakami T, Nagai J. Cisplatin-induced inhibition of receptor-mediated endocytosis of protein in the kidney. Kidney Int 2002;62:1707–17
  33. Choie DD, Longnecker DS, del Campo AA. Acute and chronic cisplatin nephropathy in rats. Lab Invest 1981;44:397–402